Redwire Secures $25 Million NASA Contract for Biotechnology and ISS Operations.

Redwire Corporation has been awarded a $25 million contract by NASA to provide biotechnology and on-orbit operations support for the International Space Station. The contract includes a $2.5 million task order to support drug development investigations. Redwire's expertise in microgravity technology plays a crucial role in advancing pharmaceutical research in space.

Redwire Corporation (RDW) has been awarded a $25 million contract by NASA to provide biotechnology and on-orbit operations support for the International Space Station (ISS). The contract, which has a five-year period, includes a $2.5 million task order to support drug development investigations. This latest award underscores Redwire's expertise in microgravity technology and its role in advancing pharmaceutical research in space.

The contract, a single award, indefinite-delivery/indefinite-quantity (IDIQ) agreement, allows NASA to issue task orders to Redwire for biotechnology facilities, on-orbit operations support, mission integration, and related services. Redwire's capabilities are designed to support a wide range of life and materials sciences research investigations that NASA processes annually.

Redwire's recent task order from NASA's In Space Production Applications (InSPA) program demonstrates its commitment to advancing drug development investigations on the ISS using its PIL-BOX technology. The company will provide turnkey services to manage, integrate, and facilitate experiments, as well as support on-orbit operations for NASA-funded research investigations.

John Vellinger, President of Redwire In-Space Industries, expressed gratitude for NASA's continued trust in Redwire's proven biotechnology capabilities. He emphasized the company's dedication to enabling new discoveries for NASA and the ISS science community.

Redwire, a global leader in microgravity research and development technologies, has flown hundreds of experiments on both the Space Shuttle and the ISS. Its microgravity technology has been instrumental in space biotechnology and pharmaceutical development, helping companies unlock new insights for potential therapeutics. Notable research partners include Bristol Myers Squibb, Eli Lilly and Company, and Butler University.

Redwire recently formed a new entity, SpaceMD, which will focus on growing seed crystals in orbit for use in creating new and reformulated pharmaceuticals on Earth.

References:
[1] https://www.marketscreener.com/news/redwire-receives-25-million-single-award-idiq-contract-by-nasa-to-provide-biotechnology-and-support-ce7c50dfd18cff21
[2] https://www.businesswire.com/news/home/20250828913799/en/Redwire-Awarded-%2425-Million-Single-Award-IDIQ-Contract-by-NASA-To-Provide-Biotechnology-and-Support-On-Orbit-Operations-Aboard-the-International-Space-Station
[3] https://redwirespace.com/newsroom/redwire-awarded-25-million-single-award-idiq-contract-by-nasa-to-provide-biotechnology-and-support-on-orbit-operations-aboard-the-international-space-station/